2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Deubiquitinase
  5. USP7 Isoform

USP7

USP7 (ubiquitin-specific protease 7, HAUSP) is a cysteine deubiquitinase that regulates protein stability by removing ubiquitin from diverse substrates involved in cell-cycle control, genome maintenance, and stress responses[1][2]. Mechanistically, USP7 is a central component of the USP7-MDM2-p53 signaling axis, where it deubiquitinates both p53 and its negative regulator MDM2, thereby controlling p53-dependent transcriptional programs, cell-cycle arrest, and apoptosis[3][4][5]. Under basal conditions, USP7 preferentially stabilizes MDM2, whereas alterations in USP7 activity can shift the balance of p53 signaling and cellular stress responses[3][4]. Beyond p53 regulation, USP7 contributes to genome stability and chromatin-associated regulatory processes through deubiquitination of proteins involved in DNA damage responses and epigenetic control[2][6]. Dysregulated USP7 expression or activity has been associated with multiple human cancers, where elevated USP7 function supports tumor initiation, progression, and survival pathways[1][2][7]. Compared with related deubiquitinases, USP7 is distinguished by its extensive interaction network and its dual capacity to regulate both tumor suppressors and oncogenic factors within the same signaling circuitry[3][8]. For experimental applications, selective USP7 inhibitors have been developed and shown to promote MDM2 degradation, activate p53 signaling, and induce cell-cycle arrest or apoptosis in cancer models, supporting the use of USP7 as a therapeutic target and mechanistic research tool[1][9][10].

References:

USP7 Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-13453
    BAY 11-7082
    		Inhibitor 99.98%
    BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells.
  • HY-158039
    YCH2823
    		Inhibitor 99.87%
    YCH2823 is an inhibitor of USP7 (IC50 = 49.6 nM; Kd = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors.
  • HY-136910
    USP7-797
    		Inhibitor 99.09%
    USP7-797 (USP7-IN-7) is an orally available, selective USP7 inhibitor (IC50=0.5 nmol/L) with antitumor activity. USP7-797 reduces the level of MDM2, thereby increasing the stability and activity of p53, leading to cell cycle arrest and apoptosis. USP7-797 has low nanomolar cytotoxicity against p53 mutant cancer cell lines, p53 wild-type hematological tumors, and neuroblastoma cell lines.
  • HY-101666
    HBX 41108
    		Inhibitor 98.91%
    HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research.
  • HY-148369
    U7D-1
    		Inhibitor 99.68%
    U7D-1 is a first-in-class potent and selective USP7 (ubiquitin-specific protease 7) PROTAC degrader, with a DC50 of 33 nM in RS4;11 cells. U7D-1 shows anticancer activity. U7D-1 induces apoptosis in Jeko-1 cells.
  • HY-183689
    OAT-4828
    		Inhibitor
    OAT-4828 is an orally active ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 32 nM. OAT-4828 induces antileukemic activity in B-cell-derived non-Hodgkin's lymphoma models via inhibition of USP7. OAT-4828 is applicable to research related to chronic lymphocytic leukemia.
  • HY-183282
    LC-U7-44
    		Inhibitor
    LC-U7-44 is a potent USP7 inhibitor with an IC50 of 0.96 μM. LC-U7-44 binds to the hydrophobic catalytic pocket of USP7, forming hydrogen bonds with Gln297, Arg408, Asp295, Val296, and Gln351, and hydrophobic interactions with Leu406. LC-U7-44 exerts anti-proliferative effects on prostate cancer cells. LC-U7-44 can be used for the research of prostate cancer.
  • HY-180826
    USP7 ligand-2
    		Ligand
    USP7 ligand-2 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC USP7 Degrader-2 (HY-180793.
  • HY-175360
    USP7 Ligand-Linker Conjugates 1
    		Inhibitor 99.92%
    USP7 Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for USP7 (HY-175359) and a PROTAC linker, which recruits E3 ligases. USP7 Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC USP7 Degrader-1 (HY-175358).
  • HY-175358
    PROTAC USP7 Degrader-1
    		Degrader
    PROTAC USP7 Degrader-1 is a VHL-recruiting PROTAC and USP7 degrader with binding activity to both USP7 and the VHL E3 ubiquitin ligase. PROTAC USP7 Degrader-1 recruits the VHL E3 ligase to mediate the ubiquitination and subsequent proteolytic degradation of USP7.
  • HY-153942
    USP7-IN-12
    		Inhibitor
    USP7-IN-12 (compound 1) is a potent and orally active Usp7 inhibitor with an IC50 value of 3.67 nM. USP7-IN-12 shows antiproliferative activity.
  • HY-180793
    PROTAC USP7 Degrader-2
    		Degrader
    PROTAC USP7 Degrader-2 (Compound D16) is an efficient and selective USP7 PROTAC degrader with a DC50 of 1.91 μM (in TE-12 cells). PROTAC USP7 Degrader-2 inhibits the migration of upper gastrointestinal tract (UGI) cancer cells and shows relatively weak anti-proliferative activity. PROTAC USP7 Degrader-2 can be used in the research of metastatic upper gastrointestinal cancer.
  • HY-49319
    USP7-IN-14
    		Inhibitor
    USP7-IN-14 is a Ligand for target protein for pROTAC.
  • HY-175359
    USP7-IN-19
    		Inhibitor
    USP7-IN-19 is a USP7 inhibitor. USP7-IN-19 can be used for synthesis of PROTAC USP7 Degrader-1 (HY-175358).
  • HY-159964
    USP7-IN-16
    		Inhibitor
    USP7-IN-16 (Compound 61) is a selective USP7 inhibitor with IC50 values of 5.5 nM in the FLINT assay and 2.1 nM in MM.1S cells. USP7-IN-16 exhibits antitumor activity in mice and is a promising candidate for research in the field of oncology.
  • HY-183078
    P6620
    		Inhibitor
    P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma.
  • HY-175793
    USP7 ligand-1
    		Ligand
    CST967 is a USP7 ligand, which can be used for the synthesis of PROTACs, such as CST967 (HY-160502).
  • HY-162794
    YCH3124
    		Inhibitor
    YCH3124 (compound Z33) is a USP7 inhibitor (IC50=41.9 nM) with antitumor activity. YCH3124 has good in vitro antiproliferative activity against various tumor cells including LNCaP (IC50=3.6 nM) and CHP-212 (IC50=9.9 nM). In addition, YCH3124 disrupts cell cycle progression by restricting G1 phase and induces apoptosis in CHP-212 cells.
  • HY-159175
    XM-U-14
    		Degrader
    XM-U-14 is a selective PROTAC USP7 Degrader (DC50: 0.74 nM in inducing USP7 degradation in RS4;11 cell line). XM-U-14 upregulates the levels of p53 and p21. XM-U-14 also significantly inhibits acute lymphoblastic leukemia (ALL) cell growth (IC50: 0.5 nM and 8.3 nM for RS4;11 cells and Reh cells respectively). XM-U-14 induces apoptosis and cycle arrest. XM-U-14 inhibits tumor growth. (Blue: VHL ligand (HY-159465), Black: linker (HY-W539783); Pink: USP7 inhibitor (HY-159464)).
  • HY-168121
    USP7-IN-15
    		Inhibitor
    USP7-IN-15 (compound J21) is a USP7 inhibitor, with an IC50 of 41.35 nM.
Cat. No. Product Name / Synonyms Application Reactivity